Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | Safety and efficacy of daratumumab, carfilzomib, pomalidomide & elotuzumab in POEMS syndrome

Iuliana Vaxman • 12 Jun 2022
EHA 2022
POEMS Syndrome Rare Diseases Antibodies Carfilzomib Daratumumab Elotuzumab Pomalidomide Thalidomide

Iuliana Vaxman, MD, Mayo Clinic, Rochester, MN, discusses the results of a study evaluating the safety and efficacy of daratumumab, carfilzomib, pomalidomide, and elotuzumab in patients with POEMS syndrome treated at Mayo Clinic. The study found that patients treated with these agents achieved deep responses, and there were no treatment-related deaths. In the future, it is important to assess these drugs in randomized clinical trials and determine optimal treatment sequencing strategies. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

More from Iuliana Vaxman

Selecting patients with AL amyloidosis for autoHSCT
2:11
Selecting patients with AL amyloidosis for autoHSCT
Iuliana Vaxman • 12 Jun 2022
The safety and efficacy of belantamab mafodotin in R/R multiple myeloma in the real world
1:38
The safety and efficacy of belantamab mafodotin in R/R multiple myeloma in the real world
Iuliana Vaxman • 12 Jun 2022

Related Videos

BPDCN: unmet needs, CD123-targeted therapies and novel targets
15:50
BPDCN: unmet needs, CD123-targeted therapies and novel targets
Naveen Pemmaraju • 19 Sep 2026
Phase III CARES: survival and cardiovascular outcomes with anselamimab in cardiac AL amyloidosis
2:19
Phase III CARES: survival and cardiovascular outcomes with anselamimab in cardiac AL amyloidosis
Ashutosh Wechalekar • 9 Sep 2026
Managing solitary plasmacytomas: importance of accurate imaging and bone marrow assessment
1:39
Managing solitary plasmacytomas: importance of accurate imaging and bone marrow assessment
Elena Zamagni • 25 Sep 2026
Anselamimab in AL amyloidosis: combining and sequencing with plasma cell-directed treatment
2:14
Anselamimab in AL amyloidosis: combining and sequencing with plasma cell-directed treatment
Ashutosh Wechalekar • 9 Sep 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals